Linathan (Linagliptin)

• Linagliptin is used in the management of type 2 diabetes, a chronic metabolic disorder characterized by insulin resistance.
• Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels when used with diet and exercise.
• Adjunct to metformin therapy: provides additional glycemic reduction in patients not achieving targets with metformin alone.
• Combination therapy: can be co‑administered with other oral antidiabetics to achieve individualized glycemic goals.

• Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the breakdown of the incretin hormones GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in reduced hepatic glucose output and improved post‑prandial glucose control.

Linagliptin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nasopharyngitis: mild upper‑respiratory tract infection.
• Headache: transient and usually low‑intensity.
• Dizziness: occasional light‑headedness.
• Gastrointestinal discomfort: includes nausea or abdominal pain.

Serious or Rare Side Effects

• Pancreatitis: severe abdominal pain requiring immediate medical attention.
• Severe hypersensitivity reactions: such as angioedema or Stevens‑Johnson syndrome.
• Hepatic injury: elevated liver enzymes or jaundice.

• Before initiating Linathan, clinicians should consider several safety aspects.
• Renal impairment: dose adjustment generally not required, but monitor renal function regularly.
• Hepatic impairment: use with caution; monitor liver enzymes.
• Cardiovascular disease: evaluate risk‑benefit in patients with heart failure.
• Elderly patients: monitor for hypoglycemia when combined with insulin or sulfonylureas.
• Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Linathan can interact with other medicines, requiring attention to the level of interaction.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
• Rifampin (potent inducer): may reduce linagliptin efficacy.
• Combination with insulin or sulfonylureas: increased risk of hypoglycemia.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect blood glucose control.
• ACE inhibitors or ARBs: monitor renal function when used together.
• Warfarin: monitor INR as glycemic changes can influence anticoagulation.